Description: <b>Chlorogenic acid (CGA)</b> is a polyphenol compound found in various plant-based foods, such as green coffee beans, apples, and pears.<br>
Chlorogenic acid (CGA; 5-caffeoylquinic acid) is a dietary polyphenol (coffee/tea/plant ester) whose primary biology in mammals is redox + stress-response modulation: (1) ROS scavenging/antioxidant buffering, (2) Keap1→NRF2 activation with induction of cytoprotective genes, and (3) downstream anti-inflammatory and survival/metabolic signaling changes (e.g., NF-κB, PI3K/Akt/mTOR/AMPK context-dependent). Oral exposure is PK-limited: after coffee doses, median peak plasma concentrations of CGA-related metabolites are ~1–1.5 µM (1088–1526 nM) , while many in-vitro cancer papers use 10–100+ µM, often exceeding realistic systemic exposure; effects can still be relevant in gut/liver (first-pass) but systemic tumor exposures are likely lower. Clinically, CGA has human PK evidence and extensive preclinical oncology; robust RCT-grade anticancer efficacy is not established, and NRF2 activation creates a credible radio/chemo-resistance risk in some contexts<br>
May lower blood pressure, blood sugar, and weight. May improve mood and cognitive function.
Chlorogenic acid (CGA), one of the most abundant polyphenols in the human diet, has been reported to inhibit cancer cell growth.<br>
• Inhibiting the growth of cancer cells: CGA has been shown to inhibit the growth of cancer cells in vitro and in vivo, including breast, colon, and prostate cancer cells.<br>
• Inducing apoptosis: CGA has been found to induce apoptosis (cell death) in cancer cells, which can help prevent the spread of cancer.<br>
• Reducing inflammation: CGA has anti-inflammatory properties, which can help reduce the risk of cancer by reducing chronic inflammation.<br>
• Antioxidant activity: CGA has antioxidant properties, which can help protect cells from damage caused by free radicals.<br>
-vast array of sources, present in honeysuckle, potato, cork, eucommia leaves, chrysanthemum, strawberry, mango, blueberries, mulberry leaves, and green coffee <br>
<p><b>Chlorogenic acid</b> — Chlorogenic acid (CGA) is a dietary hydroxycinnamate polyphenol, classically the caffeoyl ester of quinic acid, with 5-O-caffeoylquinic acid as the major canonical form usually meant by “chlorogenic acid.” It is best classified as a small-molecule natural product/polyphenolic phytochemical rather than an approved anticancer drug. Standard abbreviations include CGA and, in chemistry-focused literature, 5-CQA or 5-O-caffeoylquinic acid. Major natural sources include coffee beans, certain fruits, vegetables, and medicinal plants. In oncology, CGA is best viewed as a context-dependent redox, inflammatory, metabolic, and immune-modulatory scaffold with strong preclinical activity but important translation limits because oral systemic exposure is modest and many cell-culture studies use concentrations above likely plasma-achievable levels.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Redox buffering with suppression of excess ROS and oxidative injury.</li>
<li>Keap1/NRF2-axis activation with induction of cytoprotective antioxidant-response programs.</li>
<li>Inflammatory signaling suppression, especially NF-κB-linked cytokine and survival programs.</li>
<li>Antiproliferative and pro-apoptotic signaling in selected tumor models, often involving Akt, MAPK, mitochondrial stress, and caspase shifts.</li>
<li>Metabolic reprogramming effects in some models, including reduced glycolytic signaling and HIF-1α/VEGF-linked adaptation.</li>
<li>Immune-modulatory effects, including reported PD-L1 suppression and improved antitumor T-cell activity in some systems.</li>
<li>Therapy-interaction effects that can diverge by context, with chemosensitizing reports in some models but radio/chemoprotection risk where antioxidant/NRF2 effects dominate.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral CGA is moderately absorbed and extensively metabolized, not absent from circulation. However, systemic exposure is dominated by conjugated and gut-derived metabolites, while exposure to intact parent CGA is relatively limited and variable. For pharmacology, this means dietary CGA can be biologically relevant, but many in-vitro studies still use concentrations above typical circulating parent-compound levels after ordinary oral intake.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> This is a major translation constraint. Many oncology papers use roughly 10–200 µM or higher, while realistic oral systemic parent-CGA exposure is usually much lower; therefore many direct cytotoxic, anti-stemness, or signaling claims are likely more relevant to gut/liver first-pass settings, local delivery concepts, metabolite biology, or formulated/injectable products than to ordinary dietary exposure.</p>
<p><b>Clinical evidence status:</b> Extensive preclinical evidence; limited small-human oncology evidence. Early-phase clinical development exists for injectable CGA in recurrent high-grade glioma/advanced lung cancer programs, but robust randomized evidence for standard anticancer use is not established. Current evidence supports CGA mainly as a preclinical or adjunctive candidate, not a validated standalone cancer therapy.</p>
<pre>
Plant Source CGA(mg/kg in dw)
Instant coffee 2650–11,600
Mate tea 4800–24,900
Sunflower seeds 630–970
Sweet potato leaves 9600
English potato 1 3.3–9
Okra 1 3.9–21.6
Eggplant 4980–8050
Carrot 300–18,800
Tomato 200–400
</pre>
<h3>Chlorogenic Acid Mechanistic Table</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>ROS redox modulation</td>
<td>↔ mixed (context-dependent)</td>
<td>↓ ROS</td>
<td>P–R</td>
<td>Bidirectional redox modulation</td>
<td>CGA is centrally redox-active, but not in a one-direction way. In cancer cells it can either raise or lower ROS depending on model, dose, and treatment context; overall literature supports redox buffering/antioxidant behavior as the dominant general profile, while some tumor models show ROS elevation linked to cytotoxicity.</td>
</tr>
<tr>
<td>2</td>
<td>NRF2 antioxidant response</td>
<td>↑ NRF2 (context-dependent)</td>
<td>↑ NRF2</td>
<td>R–G</td>
<td>Cytoprotective gene induction</td>
<td>Important dual-use axis. In normal tissue this is often protective; in stressed tumors it can reinforce survival and treatment resistance.</td>
</tr>
<tr>
<td>3</td>
<td>NF-κB inflammatory survival signaling</td>
<td>↓ NF-κB</td>
<td>↓ NF-κB</td>
<td>R–G</td>
<td>Anti-inflammatory and anti-survival modulation</td>
<td>Frequently linked to reduced proliferation, invasion, cytokine tone, and improved immune context in preclinical models.</td>
</tr>
<tr>
<td>4</td>
<td>Mitochondrial apoptosis program</td>
<td>↑ Bax caspases; ↓ Bcl-2 (model-dependent; often higher concentration)</td>
<td>↓ stress-induced apoptosis</td>
<td>R–G</td>
<td>Programmed cell-death tuning</td>
<td>Common anticancer readout in vitro and xenografts, but often concentration-sensitive and not necessarily representative of dietary exposure.</td>
</tr>
<tr>
<td>5</td>
<td>PI3K Akt mTOR growth signaling</td>
<td>↓ PI3K Akt mTOR (model-dependent)</td>
<td>↔</td>
<td>R–G</td>
<td>Antiproliferative signaling restraint</td>
<td>Supported in several tumor systems, but usually not the single dominant axis and often intertwined with upstream redox or receptor effects.</td>
</tr>
<tr>
<td>6</td>
<td>Glycolysis and HIF-1α adaptation</td>
<td>↓ glycolysis; ↓ HIF-1α (model-dependent)</td>
<td>↔</td>
<td>R–G</td>
<td>Metabolic stress and anti-angiogenic pressure</td>
<td>Includes reports of reduced HK2, PKM2, LDHA, GLUT1, and VEGF-linked signaling in selected models; likely secondary rather than universal.</td>
</tr>
<tr>
<td>7</td>
<td>EMT invasion and metastasis circuitry</td>
<td>↓ EMT; ↓ MMP2 MMP9; ↑ epithelial markers</td>
<td>↔</td>
<td>G</td>
<td>Reduced motility and invasive phenotype</td>
<td>Seen in breast, cholangiocarcinoma, tongue, and other models; translationally interesting but still preclinical.</td>
</tr>
<tr>
<td>8</td>
<td>Immune checkpoint and antitumor immunity</td>
<td>↓ PD-L1 (model-dependent)</td>
<td>↔ to ↑ immune support</td>
<td>G</td>
<td>Potential immunotherapy support</td>
<td>One of the more interesting recent directions. May improve T-cell–mediated antitumor activity in selected systems, but remains early-stage.</td>
</tr>
<tr>
<td>9</td>
<td>Radiosensitization or chemoprotection balance</td>
<td>↔ to ↑ resistance (ROS NRF2 dominant contexts)</td>
<td>↑ protection</td>
<td>P–R</td>
<td>Therapy interaction risk</td>
<td>Not a classic radiosensitizer. In at least some HCC models CGA reduced radiotherapy efficacy through ROS scavenging and NRF2 activation.</td>
</tr>
<tr>
<td>10</td>
<td>Chemosensitization</td>
<td>↑ chemosensitivity (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Adjunct enhancement of selected anticancer drugs</td>
<td>Best described as a context-dependent secondary mechanism or therapeutic interaction. Preclinical evidence supports enhancement of some agents such as 5-FU in selected models, but this is not the core defining mechanism of CGA.</td>
</tr>
<tr>
<td>11</td>
<td>Ca²⁺ signaling</td>
<td>↔</td>
<td>↔</td>
<td>—</td>
<td>Usually secondary</td>
<td>Not a strongly established primary axis for CGA in cancer. Include only for model-specific mechanistic discussions.</td>
</tr>
<tr>
<td>12</td>
<td>Ferroptosis relevance</td>
<td>↔ to ↓ ferroptotic drive (context-dependent)</td>
<td>↔ to ↓ ferroptotic injury</td>
<td>—</td>
<td>Usually secondary and often opposing</td>
<td>CGA’s antioxidant and NRF2-linked profile more often argues against ferroptosis promotion unless paired with external pro-oxidant triggers or special formulations.</td>
</tr>
<tr>
<td>13</td>
<td>Clinical Translation Constraint</td>
<td>Low systemic parent exposure; many in-vitro effects are high-concentration</td>
<td>Better fit for protection than tumor killing in some settings</td>
<td>—</td>
<td>PK and context limitation</td>
<td>Main constraints are oral bioavailability, metabolite-dominant disposition, model heterogeneity, and potential therapy antagonism when antioxidant protection outweighs tumor suppression.</td>
</tr>
</table>
<div><b>TSF Legend:</b> P: 0–30 min (primary/rapid effects) R: 30 min–3 hr (acute signaling/stress) G: >3 hr (gene-regulatory adaptation)</div>
<br>
<br>
<h3> Alzheimer’s disease context </h3>
<p><b>Chlorogenic acid</b> — In the Alzheimer’s disease context, chlorogenic acid (CGA) is best classified as a multifunctional dietary polyphenol/neuroprotective small molecule with preclinical cholinergic, antioxidant, anti-inflammatory, and anti-amyloid activity rather than an established AD drug. Its AD relevance is supported by in vitro and animal-model evidence showing reduced acetylcholinesterase activity, lower oxidative stress, lower neuroinflammation, and improved cognitive performance in several paradigms. Standard abbreviations include CGA and 5-CQA. The strongest current interpretation is that CGA is a plausible adjunctive neuroprotective candidate with limited human cognitive-support data, but not a clinically validated treatment for Alzheimer’s disease.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Reduction of oxidative stress and lipid peroxidation.</li>
<li>Suppression of microglial activation and pro-inflammatory signaling.</li>
<li>Down-modulation of acetylcholinesterase activity with support of cholinergic tone.</li>
<li>Reduction of amyloid-related toxicity and associated neuronal injury.</li>
<li>Support of mitochondrial and autophagy-linked neuronal homeostasis in selected models.</li>
<li>Functional cognitive improvement in preclinical models, with limited human support for attention/executive domains rather than confirmed AD treatment.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral chlorogenic acids are meaningfully absorbed but extensively metabolized; circulating exposure includes parent compound plus conjugated and gut-derived phenolic metabolites. Brain penetration has been demonstrated in animal PK work, but CNS exposure is still constrained relative to many in vitro concentrations.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many neuroprotection studies use pharmacologic concentrations or dosing paradigms not directly comparable to ordinary dietary intake. AD relevance is therefore biologically plausible but still translationally constrained by metabolism, CNS exposure, and model dependence.</p>
<p><b>Clinical evidence status:</b> Strong preclinical support; limited human cognitive-support evidence; no convincing clinical evidence that CGA is an established Alzheimer’s disease therapy.</p>
<h3>Chlorogenic Acid in Alzheimer’s Disease</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Oxidative stress and lipid peroxidation</td>
<td>↓</td>
<td>R–G</td>
<td>Redox neuroprotection</td>
<td>Most consistent AD-relevant signal. CGA lowers oxidative stress markers and lipid peroxidation in amnesia and amyloid-related models.</td>
</tr>
<tr>
<td>2</td>
<td>Microglial activation and neuroinflammation</td>
<td>↓</td>
<td>R–G</td>
<td>Anti-inflammatory CNS protection</td>
<td>Supported by studies showing reduced microglial activation or M1-like inflammatory polarization with improved cognition and neuronal preservation.</td>
</tr>
<tr>
<td>3</td>
<td>Acetylcholinesterase</td>
<td>↓</td>
<td>R–G</td>
<td>Support of cholinergic function</td>
<td>AChE inhibition is supported in vitro and in animal cognitive-impairment models. This helps justify AD relevance, but the effect size and clinical comparability versus approved AChE inhibitors remain uncertain.</td>
</tr>
<tr>
<td>4</td>
<td>Amyloid β toxicity</td>
<td>↓</td>
<td>G</td>
<td>Reduced amyloid-associated neuronal damage</td>
<td>Evidence supports attenuation of Aβ-linked toxicity and, in some models, lower amyloid burden or downstream injury. This is supportive but still preclinical.</td>
</tr>
<tr>
<td>5</td>
<td>Synaptic and neuronal survival</td>
<td>↑</td>
<td>G</td>
<td>Preservation of neuronal integrity</td>
<td>CGA generally trends toward improved neuronal survival and less histologic damage in AD-like or cognitive-injury models.</td>
</tr>
<tr>
<td>6</td>
<td>Autophagy and proteostasis</td>
<td>↑ (model-dependent)</td>
<td>G</td>
<td>Improved clearance homeostasis</td>
<td>Some APP/PS1 work suggests restoration of autophagic flux and improved proteostatic handling. Relevant, but not yet the dominant AD axis for CGA.</td>
</tr>
<tr>
<td>7</td>
<td>Mitochondrial function</td>
<td>↑ (model-dependent)</td>
<td>R–G</td>
<td>Energetic stabilization</td>
<td>Often inferred from lower oxidative injury and better neuronal viability; mechanistically plausible but less directly established than antioxidant and anti-inflammatory effects.</td>
</tr>
<tr>
<td>8</td>
<td>Cognitive performance</td>
<td>↑</td>
<td>G</td>
<td>Behavioral improvement</td>
<td>Multiple rodent studies report improved learning or memory. Human evidence is limited and currently supports mild cognitive-function benefit more than established AD efficacy.</td>
</tr>
<tr>
<td>9</td>
<td>Clinical Translation Constraint</td>
<td>↔</td>
<td>—</td>
<td>Preclinical-to-clinical gap</td>
<td>Main constraints are metabolite-dominant exposure, uncertain brain-effective concentrations in humans, heterogeneous models, and lack of definitive AD treatment trials.</td>
</tr>
</table>
<div><b>TSF Legend:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</div>